Issues relating to the early or earlier use of insulin in type 2 diabetes

Practical Diabetes International

Volumn 20, Issue 2, 2003, Pages 63-71

  Home, Philip D ^a   Boulton, Andrew J M ^b   Jimenez, Jorge ^c   Landgraf, Rüdiger ^d   Osterbrink, Brigitte ^e   Christiansen, Jens Sandahl ^f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSIDAD NACIONAL DE ASUNCIÓN   (Paraguay)

^d UNIVERSITY OF MUNICH   (Germany)

^e Mathias Spital ^*  (Germany)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Insulin; Type 2 diabetes

Indexed keywords

ANOREXIGENIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; HYPERGLYCEMIC AGENT; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SECRETAGOGUE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ECONOMIC ASPECT; EMPLOYMENT; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH PROGRAM; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY FAILURE; LIVER FAILURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; POLYPHARMACY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN;

EID: 0037347745     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.433     Document Type: Review

References (75)

1. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000; 60: 95-113.
2. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomised controlled trial. Ann Intern Med 1999; 130: 389-396.
3. 1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-1241.
4. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects. Endocr Rev 1998; 19: 477-490.
5. Gerich JE. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19: 491-503.
6. UKPDS 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258.
7. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
8. UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
10. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
11. Gale EA. Lessons from the glitazones: A story of drug development. Lancet 2001; 357: 1870-1875.
12. De Sonnaville JJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998; 21: 919-924.
13. Scarlett JA, Gray RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982; 5: 353-363.
14. Romano G, Patti L, Innelli F, et al. Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 1997; 46: 1601-1606.
15. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-1659.
16. Campbell IW. Metformin and the sulphonylureas: The comparative risk. Horm Metab Res Suppl 1985; 15: 105-111.
17. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia (Technical Review). Diabetes Care 1994; 17: 734-755.
18. Gill GV, Huddle KR. Hypoglycaemic admissions among diabetic patients in Soweto, South Africa. Diabet Med 1993; 10: 181-183.
19. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: A report on 57 cases. Diabetologia 1983; 24: 412-417.
20. Asplund K, Wiholm BE, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med 1991; 8: 726-731.
21. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-29.
22. Hepburn DA, MacLeod KM, Pell AC, et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993; 10: 231-237.
23. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238-245.
24. Yki-Järvinen H, Dressler A, Ziemen M, on behalf of the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
25. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249-1255.
26. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.
27. Rasmussen BM, Orskov L, Schmitz O, Hermansen K. Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects. Metabolism 2001; 50: 451-457.
28. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994; 78: 1341-1348.
29. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-410.
30. Korzon-Burakowska A, Hopkins D, Matyka K, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998; 21: 283-290.
31. Levy CJ, Kinsley BT, Bajaj M, Simonson DC. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 1998; 21: 1330-1338.
32. Spyer G, Hattersley AT, MacDonald IA, et al. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 2000; 356: 1970-1974.
33. Berger W, Caduff F, Pasquel M, Rump A. The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984. Schweiz Med Wochenschr 1986; 116: 145-151.
34. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000; 35: 500-505.
35. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411-425.
36. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 (Suppl. 3): S21-31.
37. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.
38. Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998; 32: 243-248.
39. Sawicki PT, Baba T, Berger M, Starke A. Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J Am Soc Nephrol 1992; 3 (4 Suppl): S64-68.
40. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. Diabetologia 1999; 42: 263-285.
41. Poulsen PL, Hansen KW, Ebbehoj E, et al. No deleterious effects of tight blood glucose control on 24-hour ambulatory blood pressure in normoalbuminuric insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 155-158.
42. He J, Klag MJ, Caballero B, et al. Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med 1999; 159: 498-503.
43. Mitchell BD, Haffner SM, Hazuda HP, et al. The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. Am J Epidemiol 1992; 136: 12-22.
44. Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991; 324: 733-739.
45. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
46. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-486.
47. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: The 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000; 23: 1097-1102.
48. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991; 14: 461-469.
49. Wellborn TA, Knuiman MW, Ward N, Whittall DE. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994; 26: 51-59.
50. Jarrett RJ, McCartney P, Keen H. The Bedford survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84.
51. Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000; 43: 148-155.
52. Ruige JB, Assendelft WJ, Dekker JM, et al. Insulin and risk of cardiovascular disease: A meta-analysis. Circulation 1998; 97: 996-1001.
53. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-1817
54. Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the DIGAMI (Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction) study. Circulation 1999; 99: 2626-2632.
55. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.
56. American Diabetes Association (ADA). Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21: 296-309.
57. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
58. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Diabetes Care 1993; 16: 21-31.
59. Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with Type 2 diabetes. Diabetes Care 1997; 20: 1539-1542.
60. DCCT (Diabetes Control and Complications Trial). Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 1711-1721.
61. Chan WB, Chann JC, Chow CC, et al. Glycaemic control in type 2 diabetes: The impact of body weight, beta-cell function and patient education. QJM 2000; 93: 183-190.
62. Daly A, Kulkarne K, Boucher J. The new credential: Advanced diabetes management. J Am Diet Assoc 2001; 101: 940-943.
63. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
64. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 2000; 23: 45-50.
65. Holman RR, Turner RC. Insulin therapy in type II diabetes. Diabetes Res Clin Pract 1995; 28 (Suppl.): S179-184.
66. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-1909.
67. Turner R, Stratton I, Horton V, et al. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-1293.
68. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46: 239-246.
69. Mollema ED, Snoek FJ, Heine RJ, Van Der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: Opportunities for screening. Diabet Med 2001; 18: 671-674.
70. Hawthorne K, Tomlinson S. Pakistani moslems with Type 2 diabetes mellitus: Effect of sex, literacy skills, known diabetic complications and place of care on diabetic knowledge, reported self-monitoring management and glycaemic control. Diabet Med 1999; 16: 591-597.
71. Khan LA, Khan SA. Level of knowledge and self-care in diabetics in a community hospital in Najran. Ann Saudi Med 2000; 20: 300-301.
72. El Kebbi IM, Bacha GA, Ziemer DC, et al. Diabetes in urban African-Americans. V. Use of discussion groups to identify barriers to dietary therapy among low-income individuals with noninsulin-dependent diabetes mellitus. Diabetes Educ 1996; 22: 488-492.
73. Stern MP, Mitchell BD. Diabetes in Hispanic Americans. In: Harris MI, ed. Diabetes in America, 2nd edn: NIH Publication No. 95-1468. Washington, DC: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995; pp631-659.
74. Zimmet PZ, McCarty DJ, De Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997; 11: 60-68.
75. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999; 16: 716-730.